Tezspire Side Effects

Generic name: tezepelumab

Medically reviewed by Drugs.com. Last updated on Oct 15, 2023.

Note: This document contains side effect information about tezepelumab. Some dosage forms listed on this page may not apply to the brand name Tezspire.

Applies to tezepelumab: subcutaneous solution.

Serious side effects of Tezspire

Along with its needed effects, tezepelumab (the active ingredient contained in Tezspire) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking tezepelumab:

Incidence not known

Burning, dry, or itching eyes
chest tightness
discharge, excessive tearing
fast heartbeat
hives, itching, skin rash
hoarseness
irritation
joint pain, stiffness, or swelling
lightheadedness, dizziness, or fainting
redness, pain, swelling of the eye, eyelid, or inner lining of the eyelid
redness of the skin
swelling of the eyelids, face, lips, mouth, tongue, hands, or feet
trouble breathing

Other side effects of Tezspire

Some side effects of tezepelumab may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

Less common

Back pain
body aches or pain
cough
difficulty in moving
dryness or soreness of the throat
fever
muscle pain or stiffness
redness, pain, or itching at the injection site
stuffy or runny nose
tender, swollen glands in the neck
trouble swallowing
voice changes

For Healthcare Professionals

Applies to tezepelumab: subcutaneous solution.

General

The most common adverse reactions included pharyngitis, arthralgia, and back pain. The safety profile in pediatric patients was generally similar to the overall study population.^[Ref]

Cardiovascular

Frequency not reported: MACE (major adverse cardiovascular events)

One clinical trial observed higher incidence rates per 100 patient-years for both serious cardiac adverse events and MACE in patients treated with this drug as compared to placebo; however, the clinical implications of these findings were not described by the manufacturer.

Dermatologic

Common (1% to 10%): Rash

Rash included rash, pruritic rash, erythematous rash, maculopapular rash, and macular rash.

Hypersensitivity

Postmarketing reports: Anaphylaxis

Immunologic

Common (1% to 10%): Anti-drug antibodies

Local

Common (1% to 10%): Injection site reactions

Injection site reactions included injection site erythema, injection site swelling, and injection site pain.

In one clinical study, injection site reactions were observed in a higher percentage of patients who used the prefilled pen (5.7%) versus the prefilled syringe (0%).